

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	تد	
n re Patent Application of	)	
	)	
Kjell OLMARKER et al.	)	Group Art Unit: .1647
	)	
Application No.: 09/760,810	)	Examiner: J. Seharaseyon
	)	
Filed: January 17, 2001	)	Confirmation No.: 4391
	)	
For: USE OF CERTAIN	)	
METALLOPROTEINASE INHIBITORS	)	

RECEIVED
FEB 2:8 2003
TECH CENTER 1600/2900

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

FOR TREATING NERVE DISORDERS MEDIATED BY NUCLEUS PULPOSUS

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[X]	No additional fee for submission of an IDS is required.		
[]	The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.		
[X]	A statement under 37 C.F.R. § 1.97(e) is also enclosed.		
[ ]	A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.		
[]	Charge \$ to Deposit Account No. 02-4800 for the fee due.		
[]	A check in the amount of \$ is enclosed for the fee due.		

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: February 26, 2003

.

(12/02)